Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
State-of-the-Art Drug Cardio-Respiratory Discovery and Development in Europe
share announcement

State-of-the-Art Drug Cardio-Respiratory Discovery and Development in Europe

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: closed (15 July 2022) | Viewed by 2756

Special Issue Editor

Prof. Dr. Alice M Turner

E-Mail Website
Guest Editor
Centre for Translational Inflammation Research, University of Birmingham, Birmingham, UK
Interests: chronic obstructive pulmonary disease; Alpha 1 antitrypsin deficiency; clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This issue will focus on articles which describe all phases of drug discovery, from molecular work and early in vitro or animal studies, to clinical trials with diseases of the cardiovascular and/or respiratory system. This could include airways disease, pulmonary fibrosis, respiratory infection, ischaemic heart disease, pulmonary hypertension, cardiac failure, atrial fibrillation or other cardiorespiratory problems. Review articles about the current situation in a specific disease or disease area, which describe the landscape for treatment in the future, based on current themes in drug development, would also be of interest.

This Special Issue aims at collecting original research or review articles on Drug Cardio-respiratory Discovery and Development in Europe.

Prof. Dr. Alice M Turner
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • airways disease
  • pulmonary fibrosis
  • respiratory infection
  • ischaemic heart disease
  • pulmonary hypertension
  • cardiac failure
  • atrial fibrillation or other cardiorespiratory problems

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 852 KiB  
Article
The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
by Paolo Cameli, Valerio Alonzi, Miriana d’Alessandro, Laura Bergantini, Elena Pordon, Marco Guerrieri, Rosa Metella Refini, Piersante Sestini and Elena Bargagli
Biomedicines 2022, 10(8), 1973; https://doi.org/10.3390/biomedicines10081973 - 15 Aug 2022
Cited by 10 | Viewed by 2322
Abstract
Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated that nintedanib reduced functional disease progression also in subjects with non-IPF progressive fibrosing interstitial lung disease (PF-ILD). However, real-life data [...] Read more.
Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated that nintedanib reduced functional disease progression also in subjects with non-IPF progressive fibrosing interstitial lung disease (PF-ILD). However, real-life data on the effectiveness of nintedanib in PF-ILD and familial pulmonary fibrosis (FPF) are lacking. Methods: this retrospective monocentric study enrolled 197 patients affected with IPF, PF-ILD and FPF treated with nintedanib at the Referral Centre of Siena from 2014 to 2021. Pulmonary functional tests and survival data were collected throughout the observation period for the evaluation of mortality and disease progression outcomes. Results: nintedanib treatment significantly reduced the FVC decline rate in IPF and PF-ILD subgroups, but not in FPF subjects. No significant differences were observed among the subgroups in terms of survival, which appeared to be influenced by gender and impaired lung function (FVC < 70% of predicted value). Concerning disease progression rate, a diagnosis of FPF is associated with more pronounced FVC decline despite nintedanib treatment. Conclusions: our research studies the effectiveness and safety of nintedanib in reducing functional disease progression of IPF and PF-ILD. FPF appeared to be less responsive to nintedanib, even though no differences were observed in terms of survival. Full article
(This article belongs to the Special Issue State-of-the-Art Drug Cardio-Respiratory Discovery and Development in Europe)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop